Seeking Alpha

Seeking Alpha Portfolio App for iPad

3,766 people get CLSN articles and Market Currents by email alert.

Get email alerts on CLSN »

CLSN

Celsion Corporation

5/21/2013, 10:24 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 9:08 AM Celsion (CLSN) jumps 14% premarket after the company says data from a Phase III HEAT study suggests ThermoDox combined with radio frequency ablation warrants "further investigation and development … as a first line treatment for hepatocellular carcinoma." (PR) 1 Comment [Healthcare, On the Move]
Thursday, May 9, 9:39 AM Celsion (CLSN): Q1 EPS of -$0.12 beats by $0.04. Revenue of $125K misses by $65.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 23, 9:03 AM Celsion Corp (CLSN) is moving higher in pre-trading on comments from the company that its experimental cancer drug, Thermodox, shows it may now in fact be viable for the treatment of liver cancer. The comments come just months after the company warned of the drug's limited prospects, causing the stock to crater 81% in one day in January after the company suggested the drug failed to significantly slow the progression of liver cancer in a late-stage trial. Shares +14%. 1 Comment [Healthcare, On the Move, Global & FX]
Monday, March 18, 9:10 AM Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move]
Friday, March 8, 9:10 AM Premarket gainers: P +25%. TPX +9%. BVSN +7%. ANN +8%. CLSN +5%. HRB +5%.
Losers: SKUL -17%. MXWL -15%. MED -9%. GOL -6%. Comment! [On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Monday, February 11, 9:15 AM Premarket gainers: CLSN +9%. AUDC +7%.
Losers: NVO -14%. RDN -7%. CZR -7%. HEK -5%.
1 Comment [On the Move]
Monday, February 4, 12:45 PM Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move]
Monday, February 4, 12:33 PM Celsion (CLSN -11.4%) sinks again today after noting in a SEC filing that it's entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell $25M worth of shares, from time to time. The stock cratered last week on news that its liver cancer drug TheromDox had failed its latest clinical trials. 2 Comments [Healthcare, On the Move]
Friday, February 1, 4:39 PM Shares of Celsion (CLSN) added to yesterday's 79% free fall today, closing out the day with an additional 12.6% hit after touching a new 52-week low of $1.25 earlier. The downturn was sparked on Thursday after the company announced that ThermoDox did not meet the primary endpoint in a Phase III study in patients with hepatocellular carcinoma also known as primary liver cancer. 4 Comments [Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Friday, February 1, 9:10 AM Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move]
Thursday, January 31, 3:18 PM Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral on the back of the failed trial results on its experimental liver cancer drug ThermoDox. The technology failed to significantly slow the progression of liver cancer by what appears to be a wide marging, and calls into doubt the drug's near-term viability. 1 Comment [Healthcare, On the Move]
Thursday, January 31, 12:45 PM Midday top 10 gainers: ORCC +82%. WMS +52%. FTNT +24%. HHS +22%. EDMC +18%. BTUI +18%. JDSU +18%. PBI +17%. CSII +16%. SGI +16%.
Midday top 10 Losers: CLSN -81%. LQDT -24%. STZ -20%. NVGN -18%. FIO -16%. HALO -16%. RDEN -14%. USAK -13%. HAR -13%. JBSS -12%. Comment! [On the Move]
Thursday, January 31, 9:23 AM Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with primary liver cancer. The study was designed to show a 33% improvement in progression-free survival. CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox. 5 Comments [Healthcare, On the Move]
Thursday, January 31, 9:13 AM Premarket gainers: ORCC +82%. WMS +55%. FTNT +20%. SGMS +15%. JDSU +14%. KERX +14%. ALGN +13%. SWKS +13%. CTXS +12%. ERIC +11%. DCTH +7%. PBI +8%. QCOM +6%. ALU +6%. CXS +6%. FNSR +6%. LVS +6%. UA +5%. IGT +5%.
Losers: CLSN -79%. LQDT -15%. FIO -14%. RIMM -7%. AFFY -7%. RMD -6%. FB -6%. VNR -5%. 1 Comment [On the Move]